Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 2Head & Neck 2Genitourinary 2Endocrine 2CNS 2Thoracic 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Cancer, Papillary 2Sarcoma 2Salivary Gland Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

TIC10 compound 5trametinib 4dabrafenib 4Crizotinib 3selpercatinib 2naxitamab 2entrectinib 2Trastuzumab 2Granulocyte-Macrophage Colony-Stimulating Factor 2AZD 6244 2vorasidenib 1ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1tovorafenib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1mirdametinib 1lutetium Lu 177 dotatate 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1copper dotatate CU-64 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × entrectinib × CNS × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡